Combined Screening Delfia Serum

Combined Screening Delfia, Serum

Combined Screening Delfia is a prenatal blood screening test performed during the first or second trimester of pregnancy to assess the risk of certain chromosomal abnormalities and fetal conditions. The test measures specific biochemical markers in maternal serum using DELFIA (Dissociation-Enhanced Lanthanide Fluorescent Immunoassay) technology for highly sensitive detection.

Why This Test is Done

• Screens for risk of:
  • Down Syndrome (Trisomy 21)
  • Edwards Syndrome (Trisomy 18)
  • Neural Tube Defects
• Helps in early prenatal risk assessment
• Often combined with ultrasound findings for improved accuracy

Sample Type

• Serum

Test Method

• DELFIA / Fluoroimmunoassay

Preparation

• No fasting required
• Clinical details such as gestational age and maternal history may be needed

Who Should Consider This Test

• Pregnant women during routine antenatal screening
• Women with advanced maternal age
• High-risk pregnancies
• Previous history of chromosomal abnormalities

Interpretation

• Results indicate screening risk and not a definitive diagnosis
• Abnormal/high-risk results may require confirmatory diagnostic tests such as amniocentesis or NIPT

Reporting Time

• Usually within 24–72 hours depending on laboratory workflow